BACKGROUND AND OBJECTIVES: The aim of this study was to clarify the clinicopathological differences between patients with invasive intraductal papillary-mucinous neoplasm (IPMN) of the pancreas and pancreatic ductal adenocarcinoma. METHODS: The medical records of 16 patients with invasive IPMN and 106 patients with pancreatic ductal adenocarcinoma, who underwent surgical resection, were retrospectively reviewed, and the clinicopathological factors and survival were compared between the two groups. RESULTS: The presence of retroperitoneal tissue invasion, portal or splenic vein invasion, nodal involvement, and positive surgical margins were significantly lower in patients with invasive IPMN than in those with ductal adenocarcinoma (P < 0.05). The actuarial 5-year overall survival rates in patients with invasive IPMN and ductal carcinoma were 40% and 18%, respectively (P = 0.008). However, the actuarial 5-year survival rate of patients with invasive IPMN was only 27% for UICC stage II disease, although this was significantly higher than that of patients with UICC stage II ductal adenocarcinoma (P = 0.049). CONCLUSIONS: Invasive IPMN has a favorable prognosis compared with pancreatic ductal adenocarcinoma that is likely due to the less aggressive nature of the disease. However, the prognosis for cases of advanced invasive IPMN is not always favorable despite complete tumor resection. (c) 2009 Wiley-Liss, Inc.
BACKGROUND AND OBJECTIVES: The aim of this study was to clarify the clinicopathological differences between patients with invasive intraductal papillary-mucinous neoplasm (IPMN) of the pancreas and pancreatic ductal adenocarcinoma. METHODS: The medical records of 16 patients with invasive IPMN and 106 patients with pancreatic ductal adenocarcinoma, who underwent surgical resection, were retrospectively reviewed, and the clinicopathological factors and survival were compared between the two groups. RESULTS: The presence of retroperitoneal tissue invasion, portal or splenic vein invasion, nodal involvement, and positive surgical margins were significantly lower in patients with invasive IPMN than in those with ductal adenocarcinoma (P < 0.05). The actuarial 5-year overall survival rates in patients with invasive IPMN and ductal carcinoma were 40% and 18%, respectively (P = 0.008). However, the actuarial 5-year survival rate of patients with invasive IPMN was only 27% for UICC stage II disease, although this was significantly higher than that of patients with UICC stage II ductal adenocarcinoma (P = 0.049). CONCLUSIONS: Invasive IPMN has a favorable prognosis compared with pancreatic ductal adenocarcinoma that is likely due to the less aggressive nature of the disease. However, the prognosis for cases of advanced invasive IPMN is not always favorable despite complete tumor resection. (c) 2009 Wiley-Liss, Inc.
Authors: Mari Mino-Kenudson; Carlos Fernández-del Castillo; Yoshifumi Baba; Nakul P Valsangkar; Andrew S Liss; Maylee Hsu; Camilo Correa-Gallego; Thun Ingkakul; Rocio Perez Johnston; Brian G Turner; Vasiliki Androutsopoulos; Vikram Deshpande; Deborah McGrath; Dushyant V Sahani; William R Brugge; Shuji Ogino; Martha B Pitman; Andrew L Warshaw; Sarah P Thayer Journal: Gut Date: 2011-04-20 Impact factor: 23.059
Authors: Minna K Lee; Joseph DiNorcia; Lisa J Pursell; Marc M Holden; Wei-Yann Tsai; Peter D Stevens; Nicole Goetz; Victor R Grann; John A Chabot; John D Allendorf Journal: J Gastrointest Surg Date: 2010-09-08 Impact factor: 3.452
Authors: Jacob R Miller; Juliana E Meyer; Joshua A Waters; Mohammad Al-Haddad; John Dewitt; Stuart Sherman; Keith D Lillemoe; C Max Schmidt Journal: HPB (Oxford) Date: 2011-09-09 Impact factor: 3.647
Authors: Takashi Muraki; Kee-Taek Jang; Michelle D Reid; Burcin Pehlivanoglu; Bahar Memis; Olca Basturk; Pardeep Mittal; David Kooby; Shishir K Maithel; Juan M Sarmiento; Kathleen Christians; Susan Tsai; Douglas Evans; Volkan Adsay Journal: Mod Pathol Date: 2021-09-13 Impact factor: 7.842
Authors: Jeremy Sharib; Laura Esserman; Eugene J Koay; Anirban Maitra; Yu Shen; Kimberly S Kirkwood; Elissa M Ozanne Journal: Surgery Date: 2020-07-29 Impact factor: 3.982